N-acetylcysteine for COPD: The evidence remains inconclusive

The Lancet Respiratory Medicine

Volumn 2, Issue 4, 2014, Pages

  Turner, Richard D ^a   Bothamley, Graham H ^a  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; CORTICOSTEROID; PLACEBO; SCAVENGER;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HOSPITAL ADMISSION; HUMAN; LETTER; LOWER RESPIRATORY TRACT INFECTION; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; UNITED KINGDOM; COMPLICATION; FEMALE; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACETYLCYSTEINE; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84897933941     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70054-2     Document Type: Letter

References (6)

1. Zheng J-P, Wen F-Q, Bai C-X, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014, 2:187-194. on behalf of the PANTHEON study group.
2. Burge S, Wedzicha J COPD exacerbations: definitions and classifications. Eur Resp J 2003, 21:46S-53S.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
4. 2 agonists) study group.
5. Cazzola M, Matera MG N-acetylcysteine in COPD may be beneficial, but for whom?. Lancet Respir Med 2014, 2:166-167.
6. Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance 2011, National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence, London.